- Details
- Matt Cooperberg hosts a discussion with Peter Carroll and Laurence Klotz examining their roles in the progress of active surveillance for low-risk prostate cancer and how they incorporate this treatment into clinical practice. They discuss the change in the field from over-detection and overtreatment where radiation and surgery were the primary treatment options to the evolution of active surveill...
|
- Details
- Peter Albers discusses his study of baseline PSA screening of young men across the nation of Germany. The study consists of 45-year-old men who are randomized in two cohorts, one group gets a PSA immediately and the other cohort has a delay of five years. The initial PSA value determines the patient’s risk-adapted strategy and dictates the schedule of further testing. Dr. Albers states that the tr...
|
- Details
- Daniel Spratt presents on practical aspects of the technological evolution in radiation therapy during the 2019 LUGPA CME session. He focuses his presentation on technological advances in radiation therapy including a hybrid of software and hardware, which is the technology of our ability to plan radiation therapy going from a 2D to 3D to IMRT era, imaging tumors when you put a patient on a machin...
|
- Details
- Sigrid Carlsson joins Charles Ryan discussing the epidemiologic outcomes of men in the current era who are facing active surveillance. She reviews the long term data learned from the Memorial Sloan Kettering Cancer Center Experience which mirrors prior reports with low rates of metastasis or cancer-related deaths for patients on active surveillance. They also discuss the migration of pushing the e...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Professor June Chan joins Charles Ryan to discuss her work with patients on active surveillance (AS) for prostate cancer and a current ongoing study of lifestyle modification. Early data suggest that exercise after diagnosis could help with delaying or deterring prostate cancer recurrence or progression. The AS RCT study...
|
- Details
- Matthew Cooperberg discusses active surveillance as the standard of care for men with low-risk prostate cancer as well as data from multiple registries including CaPSURE, MUSIC, AQUA, and SEER, which report increasing rates of active surveillance in men with low-risk disease. He further discusses the factors that may be driving lower uptake of active surveillance in some practices. Biographies: Ma...
|
- Details
- Benjamin Lowentritt and Alicia Morgans discuss the ProVent trial, the use of sipuleucel-T in newly diagnosed prostate cancer patients on active surveillance. They discuss inclusion criteria, trial design and primary outcome measures which include assessing the efficacy of sipuleucel-T in reducing reclassification to a higher Gleason grade in patients on active surveillance. Biographies: Alicia Mor...
|
- Details
- Lorelei Mucci and Alicia Morgans discuss the findings of a large epidemiologic study examining physical activity and its influence on a wide range of biological processes including anti-inflammatory and insulin pathways, may be linked to a lower risk of prostate cancer. In addition to being one of the largest of its kind, the study stands out in that researchers were able to examine medical record...
|
- Details
- (Length of Discussion: 20 min) Herb Lepor presents the current optimal management of localized prostate cancer including an in-depth review of focal ablation. He highlights technique, criteria for appropriate patient selection, and the value of counseling to managing expectations. Biography: Herbert Lepor, MD, Professor, Department of Urology, Professor, Department of Biochemistry and Molecular Ph...
|
- Details
- (Length of interview: 16 min) Mike Harrison and Chuck Ryan dialogue on the specifics of the EXTEND trial. This is a phase 2 trial evaluating the safety and efficacy of exercise training in men receiving enzalutamide plus conventional ADT for hormone naïve prostate cancer. The discussion ensues to the value of exercise in this patient population and some of the nuances in managing patients in this...
|
